Beranda › Limfoma Burkitt › New York › Rochester
Uji klinis Limfoma Burkitt di Rochester, NY
4 studi untuk Limfoma Burkitt mencari peserta di lokasi sekitar Rochester (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
Menerima pesertaFase 3
- University of Rochester, Rochester
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
Menerima pesertaFase 2
- University of Rochester, Rochester
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Menerima pesertaFase 2
- University of Rochester, Rochester
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Menerima pesertaFase 3
- University of Rochester, Rochester
Uji klinis Limfoma Burkitt di kota lain
- Houston, TX21 studi
- Philadelphia, PA16 studi
- Milwaukee, WI16 studi
- Chicago, IL15 studi
- Cincinnati, OH13 studi
- New York City, NY13 studi
- Atlanta, GA12 studi
- Aurora, CO11 studi
- Seattle, WA11 studi
- Durham, NC10 studi
- Boston, MA10 studi
- Kansas City, MO10 studi
Studi lain di Rochester
- Leukemia Mieloid Akut16 studi
- Kanker Paru15 studi
- Kanker Payudara15 studi
- Kanker (semua jenis)14 studi
- Obesitas14 studi
- Kelebihan Berat Badan13 studi
- Kanker Paru Non-Sel Kecil13 studi
- Kanker Prostat10 studi
- Kanker Metastatik8 studi
- Mieloma Multipel8 studi
- Kanker Kandung Kemih7 studi
- Distrofi Miotonik7 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.